HY-108507-1mg
|
MedChemexpress LLC
|
MRT-10 [CAS 330829-30-6]
|
|
Cancer-programmed cell death
|
|
HY-108507-10mg
|
MedChemexpress LLC
|
MRT-10 [CAS 330829-30-6]
|
|
Cancer-programmed cell death
|
|
HY-108507-25mg
|
MedChemexpress LLC
|
MRT-10 [CAS 330829-30-6]
|
|
Cancer-programmed cell death
|
|
HY-108507-5mg
|
MedChemexpress LLC
|
MRT-10 [CAS 330829-30-6]
|
|
Cancer-programmed cell death
|
|
HY-108507-50mg
|
MedChemexpress LLC
|
MRT-10 [CAS 330829-30-6]
|
|
Cancer-programmed cell death
|
|
HY-108507-1mL
|
MedChemexpress LLC
|
MRT-10 [CAS 330829-30-6] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
HY-10559-10mg
|
MedChemexpress LLC
|
Nelotanserin [CAS 839713-36-9]
|
|
Cancer-programmed cell death
|
|
HY-10559-100mg
|
MedChemexpress LLC
|
Nelotanserin [CAS 839713-36-9]
|
|
Cancer-programmed cell death
|
|
HY-10559-25mg
|
MedChemexpress LLC
|
Nelotanserin [CAS 839713-36-9]
|
|
Cancer-programmed cell death
|
|
HY-10559-5mg
|
MedChemexpress LLC
|
Nelotanserin [CAS 839713-36-9]
|
|
Cancer-programmed cell death
|
|
HY-10559-50mg
|
MedChemexpress LLC
|
Nelotanserin [CAS 839713-36-9]
|
|
Cancer-programmed cell death
|
|
HY-10559-1mL
|
MedChemexpress LLC
|
Nelotanserin [CAS 839713-36-9] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
HY-P2185A-1mg
|
MedChemexpress LLC
|
NFF-3 (TFA)
|
|
|
|
HY-P2185A-10mg
|
MedChemexpress LLC
|
NFF-3 (TFA)
|
|
|
|
HY-P2185A-5mg
|
MedChemexpress LLC
|
NFF-3 (TFA)
|
|
|
|
HY-109066-10mg
|
MedChemexpress LLC
|
Olinciguat [CAS 1628732-62-6]
|
|
COVID-19-immunoregulation
|
|
HY-109066-100mg
|
MedChemexpress LLC
|
Olinciguat [CAS 1628732-62-6]
|
|
COVID-19-immunoregulation
|
|
HY-109066-5mg
|
MedChemexpress LLC
|
Olinciguat [CAS 1628732-62-6]
|
|
COVID-19-immunoregulation
|
|
HY-109066-50mg
|
MedChemexpress LLC
|
Olinciguat [CAS 1628732-62-6]
|
|
COVID-19-immunoregulation
|
|
HY-109066-1mL
|
MedChemexpress LLC
|
Olinciguat [CAS 1628732-62-6] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
HY-12522-10mg
|
MedChemexpress LLC
|
PF-06380101 [CAS 1436391-86-4]
|
|
Cancer-programmed cell death
|
|
HY-12522-100mg
|
MedChemexpress LLC
|
PF-06380101 [CAS 1436391-86-4]
|
|
Cancer-programmed cell death
|
|
HY-12522-25mg
|
MedChemexpress LLC
|
PF-06380101 [CAS 1436391-86-4]
|
|
Cancer-programmed cell death
|
|
HY-12522-5mg
|
MedChemexpress LLC
|
PF-06380101 [CAS 1436391-86-4]
|
|
Cancer-programmed cell death
|
|
HY-12522-50mg
|
MedChemexpress LLC
|
PF-06380101 [CAS 1436391-86-4]
|
|
Cancer-programmed cell death
|
|